In Q2 2025, VERIGRAFT achieved a major clinical milestone as the final patient visit in the TECVI-1 trial took place. As Q3 continues, preparations for pivotal phase II trials are in full motion, including strategic negotiations with CROs and contract manufacturers.
During the second quarter of 2025, VERIGRAFT reached a key clinical milestone as the final patient visit in the ongoing phase I/II TECVI-1 trial took place in June. Data validation is currently underway, forming the foundation for the next phase of clinical reporting and analysis.
All core R&D and infrastructure projects – including 4DBR, TELEGRAFT and PREPPER – progressed according to plan. Patent activity also continued across both European and international jurisdictions, supporting our long-term IP strategy.
As Q3 unfolds, our focus is on delivering validated trial data, advancing strategic partnerships, and submitting new applications for EU-based non-dilutive funding. This includes ongoing preparations for pivotal phase II trials in multiple European countries, as well as active negotiations with CROs and contract manufacturing partners.